Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year Median Follow-Up Update of PURE-01 Trial.
Giuseppe BasileMarco BandiniEwan A GibbJeffery S RossDaniele RaggiLaura MarandinoTiago Costa de PaduaEmanuele CrupiRenzo ColomboMaurizio ColecchiaRoberta LucianòLuigi NoceraMarco MoschiniAlberto BrigantiFrancesco MontorsiAndrea NecchiPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
At a median follow-up of three years, PURE-01 results further confirm the sustained efficacy of neoadjuvant pembrolizumab before RC. PD-L1 expression was the strongest predictor of sustained response post-RC.